STOCK TITAN

Annexon: BVF reports approximately 4.4% ownership

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Annexon, Inc. (ANNX) is the issuer named in Amendment No. 5 to a Schedule 13G, which reports that BVF Partners L.P., BVF Inc., and Mark N. Lampert may each be deemed to beneficially own 8,278,164 shares, approximately 4.4%, as of September 30, 2026. Each is reported with shared voting and dispositive power over that amount. Mark N. Lampert is identified as a director and officer of BVF Inc.

The underlying fund positions reported were 4,357,866 shares for Biotechnology Value Fund, L.P., 3,266,798 for Biotechnology Value Fund II, L.P., and 522,906 for Biotechnology Value Trading Fund OS LP. The filing states that the reporting does not itself constitute an admission that one reporting person beneficially owns another’s shares; several related reporting persons disclaim such ownership.

Beneficial ownership attributed to each of three reporting persons 8,278,164 shares BVF Partners L.P., BVF Inc., and Mark N. Lampert; as of September 30, 2026
Reported ownership percentage approximately 4.4% For BVF Partners L.P., BVF Inc., and Mark N. Lampert as of September 30, 2026
Biotechnology Value Fund, L.P. beneficial ownership 4,357,866 shares As of September 30, 2026
Biotechnology Value Fund II, L.P. beneficial ownership 3,266,798 shares As of September 30, 2026
Biotechnology Value Trading Fund OS LP beneficial ownership 522,906 shares As of September 30, 2026
Shares outstanding 189,579,134 shares As of August 10, 2026; used to calculate reported ownership percentages
beneficial ownership regulatory
"Amount beneficially owned"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
shared voting power regulatory
"Shared Voting Power"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive power regulatory
"Shared Dispositive Power"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





03589W102

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



BIOTECHNOLOGY VALUE FUND L P
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF I GP LLC
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BIOTECHNOLOGY VALUE FUND II LP
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF II GP LLC
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
Biotechnology Value Trading Fund OS LP
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF Partners OS Ltd.
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF GP HOLDINGS LLC
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF PARTNERS L P/IL
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF INC/IL
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
LAMPERT MARK N
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert
Date:11/16/2026

Keep reading